TRUQAP® (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial

First and only AKT inhibitor combination to demonstrate benefit in this specific subtype of prostate cancer

Excerpt from the Press Release:

WILMINGTON, Del.–(BUSINESS WIRE)–Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s TRUQAP^® (capivasertib)in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC).

Overall survival (OS) data were immature at the time of this analysis; however, the TRUQAP combination showed an early trend towards an OS improvement versus abiraterone and ADT with placebo. The trial will continue as planned to further assess OS as a key secondary endpoint.

Prostate cancer is the second most prevalent cancer in men and the fifth leading cause of male cancer death globally.¹ Only one-third of patients with metastatic prostate cancer survive five years after diagnosis.² Newly diagnosed mHSPC is an aggressive form of the disease associated with poor outcomes and survival.^3,4 Approximately 200,000 patients are diagnosed with mHSPC each year, and one in four have PTEN-deficient tumors.⁵ Patients with a tumor biomarker of PTEN deficiency have a particularly poor prognosis.⁶

Click the button below to read the entire Press Release:

Continue Reading The Press Release